Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Short-term Investments (2020 - 2026)

RxSight filings provide 6 years of Short-term Investments readings, the most recent being $208.2 million for Q4 2025.

  • On a quarterly basis, Short-term Investments fell 5.6% to $208.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $208.2 million, a 5.6% decrease, with the full-year FY2025 number at $208.2 million, down 5.6% from a year prior.
  • Short-term Investments hit $208.2 million in Q4 2025 for RxSight, up from $197.9 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $220.5 million in Q4 2024 to a low of $20.0 million in Q2 2021.
  • Median Short-term Investments over the past 5 years was $135.0 million (2021), compared with a mean of $143.9 million.
  • Biggest five-year swings in Short-term Investments: surged 423.13% in 2022 and later crashed 35.14% in 2024.
  • RxSight's Short-term Investments stood at $135.0 million in 2021, then tumbled by 30.38% to $94.0 million in 2022, then increased by 25.03% to $117.5 million in 2023, then soared by 87.69% to $220.5 million in 2024, then dropped by 5.6% to $208.2 million in 2025.
  • The last three reported values for Short-term Investments were $208.2 million (Q4 2025), $197.9 million (Q3 2025), and $187.1 million (Q2 2025) per Business Quant data.